Aby Mathew Sells 405 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby Mathew sold 405 shares of BioLife Solutions stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $25.59, for a total value of $10,363.95. Following the completion of the sale, the executive vice president owned 349,350 shares of the company’s stock, valued at $8,939,866.50. This trade represents a 0.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BioLife Solutions Price Performance

Shares of BLFS stock opened at $24.86 on Friday. The firm’s 50-day simple moving average is $25.41 and its 200-day simple moving average is $24.83. BioLife Solutions, Inc. has a 1-year low of $19.10 and a 1-year high of $29.62. The firm has a market cap of $1.20 billion, a P/E ratio of -355.09 and a beta of 1.93.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. UBS Group reaffirmed a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. Northland Securities set a $34.00 price target on BioLife Solutions in a research report on Monday. Zacks Research lowered BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Finally, HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of BioLife Solutions in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $32.00.

Key Headlines Impacting BioLife Solutions

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Analyst support that could limit downside — Northland has a $34 target and UBS maintains a buy rating; MarketBeat shows a consensus “Hold” with an average price target near $32, which provides a possible upside reference for investors. MarketBeat BLFS Analyst Coverage
• Neutral Sentiment: Company announced the planned retirement of a key quality & operations executive (effective date/details in the filing). A planned/announced retirement can be orderly but raises succession and continuity questions for manufacturing/quality functions. BioLife announces planned retirement
• Neutral Sentiment: Analysts are issuing Q1 earnings forecasts for BLFS; investors should watch upcoming guidance/quarterly results for confirmation of demand trends in cryopreservation and cell/gene therapy supply chains. Analysts Issue Forecasts for BLFS Q1 Earnings
• Negative Sentiment: Multiple insider sales reported on the same filing period — EVP Aby Mathew sold 405 shares, CMO Todd Berard sold 344 shares, CFO Troy Wichterman sold 990 shares, plus additional smaller officer/insider sales (Sarah Aebersold, Karen Foster). All sales were executed around Jan 6 at ~ $25.59; while sizes are small relative to holdings, clustered executive selling can spook investors. Insider selling report

Institutional Trading of BioLife Solutions

A number of institutional investors have recently added to or reduced their stakes in the business. State of Wyoming increased its holdings in BioLife Solutions by 353.1% in the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 1,490 shares in the last quarter. Hantz Financial Services Inc. boosted its position in shares of BioLife Solutions by 54.1% in the third quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 659 shares during the period. Quarry LP boosted its position in shares of BioLife Solutions by 50.9% in the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 713 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of BioLife Solutions by 12.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 441 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in shares of BioLife Solutions by 82.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,425 shares of the medical equipment provider’s stock valued at $113,000 after buying an additional 1,994 shares during the period. 93.24% of the stock is owned by hedge funds and other institutional investors.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.